This Event Has Now Run
Thank you to our speakers, sponsors, and delegates who joined us in London!
If you are interested in the 2026 event, please get in touch at: info@hansonwade.com
Uniting European Cell Engager & Bispecific Antibody Leaders to Optimise Targeting, Safety & Translational Research in Oncology & Autoimmune Indications
Fresh from the success of our Boston meeting, we’re brang the momentum to Europe for the very first time. This dedicated forum united leading minds in preclinical research, translational science, immunology, and oncology drug development to unlock the full potential of T-cell engagers and accelerate their path to the clinic.
The field is moving at unprecedented speed: with 8 TCE approvals, the space is attracting record investment and partnerships – AbbVie’s $2.1B deal with Xilio and Sanofi’s €15M partnership with Innate Pharma being just two examples. As pharma and biotech double down on next-generation immunotherapies, the race is on to push the boundaries of what TCEs can achieve.
But challenges remain. Target selection, bioavailability, immunogenicity, and translational hurdles continue to limit therapeutic windows, while the expansion into autoimmune disease opens new complexities and opportunities. This summit brang together the leaders driving innovation to overcome these barriers and redefined the future of TCEs.
The conference was hyper focused and really provided a good sense of what the current cell engager landscape was. I also appreciated the directed networking time and felt that with such a small group it was easy to get to know people and learn about what is in the pipeline. – InhibRx
It was great to have many opportunities to network with folks. I especially enjoyed the breadth and quality of the talks. – Boehringer Ingelheim
Enjoyed meeting with others who work in the same field and discussing opportunities and challenges with them. – Pfizer
What You Missed:
- Unlocked synergistic potential – We heard from Regeneron and Zymeworks on how co-stimulation strategies (CD28, CD137, CD2) can supercharge T cell fitness and cytotoxic responses.
- Tackled preclinical limitations – Learnt from Amgen, Roche, and NovalGen on addressing hyperactivated T cells and improving translatability.
- Going beyond traditional engagers – We explored novel modalities including AstraZeneca’s TITAN nanobody platforms, BIOMUNEX’s MAIT engagers, and NK cell engagers from Peipp’s lab.
- Expanded into autoimmunity – Gained insights from Cullinan, IN8Bio, and Cue Biopharma as they shared clinical and preclinical progress in targeting B cell subsets and pathogenic immune cells.
This was the opportunity to join the first-ever European community dedicated to T-cell engagers, where science, strategy, and collaboration converged to drive the next generation of immunotherapies.
2025 Speakers
Attending Companies Included
Explore the 2025 Agenda
Dive into cutting-edge T-cell engager science with insights from leading biopharma, biotech, and academic experts.
Partner With Us
Showcase your technologies and services to decision-makers driving next-generation TCE innovation.
Join Biopharma Experts
Be part of the only European meeting uniting immunology, biology, preclinical, and translational experts in the TCE space.